© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Fidelity Advisor Biotechnology Fund Class A (FBTAX) stock declined over -0.02%, trading at $48.01 on NASDAQ, down from the previous close of $48.02. The stock opened at $48.02, fluctuating between $48.01 and $48.02 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 48.02 | 48.02 | 48.01 | 48.01 | 0 |
| Sep 10, 2026 | 48.50 | 48.50 | 48.02 | 48.02 | 0 |
| Sep 09, 2026 | 49.20 | 49.20 | 48.50 | 48.50 | 0 |
| Sep 08, 2026 | 49.80 | 49.80 | 49.20 | 49.20 | 0 |
| Sep 04, 2026 | 49.91 | 49.91 | 49.80 | 49.80 | 0 |
| Sep 03, 2026 | 49.31 | 49.91 | 49.31 | 49.91 | 0 |
| Sep 02, 2026 | 49.31 | 49.93 | 49.31 | 49.93 | 0 |
| Sep 01, 2026 | 49.09 | 49.31 | 49.09 | 49.31 | 0 |
| Aug 31, 2026 | 49.00 | 49.09 | 49.00 | 49.09 | 0 |
| Aug 28, 2026 | 50.50 | 50.50 | 49.00 | 49.00 | 0 |
| Aug 27, 2026 | 50.81 | 50.81 | 50.50 | 50.50 | 0 |
| Aug 26, 2026 | 50.63 | 50.81 | 50.63 | 50.81 | 0 |
| Aug 25, 2026 | 50.63 | 51.46 | 50.63 | 51.46 | 0 |
| Aug 24, 2026 | 51.04 | 51.04 | 50.63 | 50.63 | 0 |
| Aug 21, 2026 | 50.47 | 51.04 | 50.47 | 51.04 | 0 |
| Aug 20, 2026 | 52.27 | 52.27 | 50.47 | 50.47 | 0 |
| Aug 19, 2026 | 49.67 | 52.27 | 49.67 | 52.27 | 0 |
| Aug 18, 2026 | 47.79 | 49.67 | 47.79 | 49.67 | 0 |
| Aug 17, 2026 | 47.79 | 48.45 | 47.79 | 48.45 | 0 |
| Aug 14, 2026 | 47.87 | 47.87 | 47.79 | 47.79 | 0 |
Boston, MA 2210
United States
https://fundresearch.fidelity.com/mutual-funds/summary/315918516877 208 0098Seeking to achieve capital growth, this fund primarily allocates its assets to common stocks. A minimum of 80% of its portfolio is typically invested in companies deeply engaged in the biotechnology sector, encompassing those involved in the research, development, manufacturing, and distribution of biotech products and services, or firms positioned to significantly benefit from scientific and technological progress in the field. The fund's holdings include securities from both domestic and foreign issuers. Investment selection is guided by fundamental analysis, evaluating factors such as the financial standing and industry position of individual companies, alongside broader market and economic conditions. It operates as a non-diversified fund.
| Employees | 0 |
| Beta | 0.62 |
| Sales or Revenue | $486.11M |
| 5Y Sales Change% | 0.455% |
| Fiscal Year Ends | February |
| Sector | Financial Services |
| Industry | Asset Management |